Press Release

Printer Friendly Version View printer-friendly version
<< Back
BeyondSpring to Host Fourth-Quarter and Full-Year 2017 Financial Results Conference Call on April 3, 2018

NEW YORK, March 27, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced that the Company will report fourth-quarter and full-year 2017 financial results on Tuesday, April 3, 2018. BeyondSpring’s management team will host a conference call and webcast at 8:00 a.m. Eastern Time on Tuesday, April 3, 2018, to discuss the financial results and provide an operational update.

The conference call may be accessed by dialing (866) 362-6591 (U.S.) or (706) 758-3199 (international) and referencing conference ID 3765248. A live webcast will be available on the Investors page of the Company's website at http://ir.beyondspringpharma.com. An archived replay of the webcast will be available for 30 days.

About BeyondSpring
BeyondSpring is a global, clinical-stage biopharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from collaboration with University of Washington in de novo drug discovery using ubiquitination platform. BeyondSpring’s lead asset, Plinabulin, is in a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer (Study 103) and two Phase 2/3 clinical programs in the prevention of chemotherapy-induced neutropenia (CIN) – (Studies 105 and 106). BeyondSpring has a seasoned management team with many years of experience bringing drugs to market.

Contact:

Investor Relations:
Laura Perry or Joe Rayne
Argot Partners
212.600.1902
BeyondSpring@argotpartners.com

BeyondSpring, Inc.
Print Page Print Page | Email Page Email Page | RSS Feeds RSS Feeds | Email Alerts Email Alerts | IR Contacts Contact IR | Financial Tear Sheet Financial Tear Sheet